Page 54 - 2023 Westchester County Economic Development Guide
P. 54
52
WESTCHESTER COUNTY ECONOMIC DEVELOPMENT GUIDE
Cultivating and Advancing Talent Regeneron
Delivering
Life-Transforming
Medicines
Above: With nearly 12,000 employees, Regeneron is a
major employer in New York State. Opposite, Top: Regeneron broke ground on its $1.8 billion expansion in Westchester County in June 2022. Opposite, Middle Regeneron Founder and CEO Leonard Schleifer at the Company’s Annual Volunteer Day Opposite, Bottom: Regeneron’s portfolio addresses cancer, macular degeneration and a host of other serious diseases.
Celebrating 35 years as a company in 2023, Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. With over 30 investigational medicines across a range of indications, Regeneron now has 11,800+ employees, around 3,700 of whom work in Westchester.
Developing New Medicines
for Serious Diseases
In 2022, Regeneron continued bringing its homegrown medicines, including EYLEA® (aflibercept), Dupixent® (dupilumab) and Libtayo® (cemiplimab-rwlc), to more patients in need. Other highlights from the year include:
• Food and Drug Administration (FDA) and European Commission (EC) approval of Dupixent for prurigo nodularis, making it the first and only medicine specifically indicated to treat this debilitating chronic skin disease, and marking the fih approved indication for this important medicine.
• FDA approval of Dupixent as the first biologic medicine for children with atopic dermatitis, and FDA and EC approval as the first treatment for adults and children (12+) with eosinophilic esophagitis.
Tarrytown-based Regeneron is “doing
well by doing good,” and working to build a better workplace, better science and a better world.
• Positive results seen from the aflibercept 8 mg pivotal trials, which demonstrated the potential to help patients with diabetic macular edema and wet age-related macular degeneration.
• Recognition of InmazebTM (atoltivimab, maivimab, and odesivimab-ebgn) as the “Best Biotechnology Product” of 2022
at the prestigious Prix Galien USA Awards, which acknowledges extraordinary scientific innovations that improve the human condition.
e Company made exciting strides for its novel oncology portfolio.
• FDA approval of Libtayo as a first-line treatment for advanced non-small-cell lung cancer in combination with chemotherapy.
• e EC and Japan approval of Libtayo for treatment of metastatic cervical cancer.
• e purchase of Sanofi’s stake in the Regeneron/Sanofi collaboration on Libtayo, obtaining exclusive right to develop, commercialize and manufacture the oncology treatment worldwide.
• e acquisition of Checkmate Pharmaceuticals, Regeneron’s first-ever acquisition of another biotechnology company, deepening its commitment to immuno-oncology.
© Courtesy of Regeneron
